All In Biotech

Investigational drug · Phase 3

BCD-217

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Melanoma Stage III, Melanoma (Skin), Melanoma.

Phase 3

Last checked: Nov 19, 2026Latest source record: Jul 8, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

2

2 still active

All registered trials

3

Any phase or sponsor naming "BCD-217"

First trial start

2022

Aug 2, 2022

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "BCD-217", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Melanoma Stage III
  • Melanoma (Skin)
  • Melanoma
  • Melanoma Stage IV
  • Melanoma Unresectable
  • Melanoma Metastatic
  • Melanoma Advanced

Approved drugs for the same conditions: Melanoma · Oncology · Dermatology

Largest trials

Live from ClinicalTrials.gov: studies naming "BCD-217" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 1 on PubMed

Also in development for Melanoma Stage III

  • L19TNFL19IL2, OnfekafuspPhase 310 trials

    Philogen S.p.A. · Glioblastoma, Locally Advanced Basal Cell Carcinoma, Melanoma Stage III

  • prolgolimabBCD-100, FortecaPhase 31 trial

    Biocad · Melanoma, Melanoma (Skin), Melanoma Stage III

  • DNA VaccinePhase 22 trials

    NEC Bio B.V · Triple Negative Breast Cancer, Malignant Melanoma, Melanoma (Skin)

  • KB707Phase 22 trials

    Krystal Biotech, Inc. · Cancer, Melanoma Stage III, Melanoma Stage IV

  • PRTX007Phase 21 trial

    Primmune Therapeutics, Inc. · Melanoma Stage III

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.